Product Mix Up Leads to Recall of Narcolepsy Drug Zenzedi
The antihistamine drug carbinoxamine was found in one bottle Zenzedi, which is used to treat narcolepsy and ADHD.
Azurity Pharmaceuticals is recalling one of Zenzedi CII (dextroamphetamine sulfate tablets) 30 mg, which used to treat patients with narcolepsy, as well as attention deficit hyperactivity disorder. A pharmacist reported finding carbinoxamine maleate, an antihistamine drug, in a bottle of Zenzedi. Zenzedi is marketed by Arbor Pharmaceuticals, a subsidiary of Azurity.
Patients who take carbinoxamine instead of Zenzedi could experience drowsiness, sleepiness, central nervous system (CNS) depression, increased eye pressure, enlarged prostate urinary obstruction, and thyroid disorder. To date, Azurity has not received any reports of serious adverse events related to this recall.
Zenzedi has an NDC number of 24338-856-03. The lot involved in the recall is F230169A with an expiration date of June 2026. It was shipped between Aug. 23, 2023, and Nov. 29, 2023.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
